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Objectives: It is not clear whether lymphadenectomy has therapeutic benefit in
non–small cell lung cancer management. To avoid unnecessary lymphadenectomy,
we attempted to identify clinical or radiologic predictors of pathologic N0 disease
in patients with peripheral adenocarcinoma.
Methods: From August 1992 through April 1997, 269 consecutive patients with
peripheral adenocarcinoma who underwent major lung resection and systematic
lymph node dissection were enrolled in this study. We reviewed their contrast-
enhancement computed tomographic scans and recorded the maximum dimension
of tumors both on pulmonary (pDmax) and on mediastinal (mDmax) window set-
ting images, the largest dimension perpendicular to the maximum axis on both pul-
monary (pDperp) and mediastinal (mDperp) window setting images, and the size of
all detectable hilar-mediastinal lymph nodes. We defined a new radiologic parame-
ter, tumor shadow disappearance rate (TDR), which is calculated with the follow-
ing formula:
TDR = 1 – .
Results: In multivariable analysis a lower serum carcinoembryonic antigen level
and a higher tumor shadow disappearance rate were significant predictors of patho-
logic N0 disease. Lymph node size on computed tomographic scanning was not a
significant predictor. Among 59 patients with a normal preoperative carcinoembry-
onic antigen level and a tumor shadow disappearance rate of 0.8 or more, 58 (98%)
patients had pathologic N0 disease, and the other patient had pathologic N1 disease.
Conclusions: Mediastinal lymph node involvement was not found in patients with a
normal preoperative serum carcinoembryonic antigen level and a tumor shadow dis-
appearance rate 0.8 or more. The patients who meet these criteria may be successfully
managed with major lung resection without systematic mediastinal lymphadenectomy.
Lobectomy or pneumonectomy plus lymphadenectomy (nodal sam-pling or systematic lymph node dissection) is the standard treatmentfor patients with resectable non–small cell lung cancer (NSCLC).Lymphadenectomy is essential in staging NSCLC correctly.However, its therapeutic benefit, if any, has not been proven. It isself-evident that lymphadenectomy would have no benefit in
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patients without mediastinal node involvement. If we could
correctly predict pathologic N0 (pN0) disease in patients
with NSCLC before operation, unnecessary lymphadenec-
tomy could be avoided.
In Japan, many small-sized NSCLCs have been found as
a result of the introduction of computed tomographic (CT)
screening for lung cancer.1 However, even NSCLC lesions
smaller than 20 mm have considerable potential for lymph
node metastasis.2,3 Small tumor size alone cannot be a rea-
son for omitting lymphadenectomy. Although clinically reli-
able predictors of pN0 disease would eliminate unnecessary
lymphadenectomy, none have yet been established.
In this study we attempted to identify clinical or radio-
logic predictors of pN0 disease in patients with peripheral
adenocarcinoma. We proposed a new radiologic parameter,
the tumor shadow disappearance rate (TDR), which was cal-
culated from the tumor shadow sizes on pulmonary window
setting images on CT scans and those on mediastinal win-
dow setting images.
Materials and Methods
From August 1992 through April 1997, 634 patients with lung cancer
underwent surgical intervention at our institute. Among them, all 269
patients with peripheral adenocarcinoma who underwent major lung
resection and systematic lymph node dissection were enrolled in this
study. Patients who had received induction therapy or had multiple
primary tumors were excluded. Contrast-enhanced CT scans were
done on an X-Vision/SP system (Toshiba, Tokyo, Japan), and con-
tiguous 10-mm thick sections were obtained from the pulmonary
apices to the bases in a supine position at full inspiration. The images
were photographed by using a pulmonary window setting (window
width, approximately 1500 to 1800 Hounsfield units [HU]; level,
approximately –650 to –550 HU) and a mediastinal window setting
(window width, approximately 380 to 420 HU; level, approximately
30 to 70 HU). The time interval between CT scanning and surgical
intervention was less than a month in all patients.
All CT scans were reviewed by 3 authors (K.T., Y.O., and K.S.),
who were not informed of the pathologic outcome, to obtain the
following information: the maximum dimension of a tumor on pul-
monary window setting images (pDmax); the largest dimension
perpendicular to the maximum axis on pulmonary window setting
images (pDperp); the maximum dimension of a tumor on medi-
astinal window setting images (mDmax); the largest dimension
perpendicular to the maximum axis on mediastinal window setting
images (mDperp); and the size of all detectable hilar-mediastinal
lymph nodes.
We defined TDR as calculated by the following formula
(Figure 1):
TDR = 1 – mDmax × (mDperp)
Figure 1. We measured pDmax and pDperp on pulmonary window setting images (A) and mDmax and mDperp on
mediastinal window setting images (B).
A B
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If multiple nodes within a single station were enlarged, the size
of the largest node was recorded. Tumor location was considered
to be central when a tumor was located in the inner one third of the
lung field on CT scanning and peripheral when in the outer two
thirds. Histologic typing was determined according to the World
Health Organization classification.4 The stage of the disease was
based on the TNM classification system of the International Union
Against Cancer.5 The mediastinal lymph node mapping on CT
scanning and thoracotomy was based on the lymph node map
described by Naruke and colleagues.6 All resected specimens were
fixed with formalin and examined microscopically by means of
standard hematoxylin and eosin staining. The clinical record of
each patient was reviewed for age, sex, smoking status, and preop-
erative serum carcinoembryonic antigen (CEA) level. Serum CEA
was measured by means of the 2-site immunoenzymometric assay
(Tosoh, Inc, Yamaguchi, Japan), and the upper normal limit for this
assay was 5 ng/mL.
Univariate and multivariable analyses were performed by the
logistic regression procedure on StatView 5.0 (Abacus Concepts,
Inc, Berkeley, Calif) to determine the relationship between pN0
disease and the following clinical or radiologic findings: age; sex;
smoking status (pack-years >40 vs ≤40); serum CEA level; both
the shortest and longest dimensions of pulmonary-mediastinal
lymph nodes; tumor dimensions (pDmax, pDperp, mDmax, and
mDperp); and TDR. The serum CEA level and smoking status
(pack-years) were severely skewed. We used continuous variables
for age, node and each tumor dimension, TDR, and log-trans-
formed serum CEA levels in statistical analyses. As for smoking
status, we used categories (ie, pack-years >40 vs ≤40) because
pack-year values showed a 2-peak distribution. TDR was a param-
eter calculated by pDmax, pDperp, mDmax, and mDperp. Thus,
we entered these 5 variables separately in a multivariable model.
Differences were considered statistically significant when the P
values were < .05.
Results
The clinicoradiologic characteristics of the patients are pre-
sented in Table 1. There were 193 (72%) patients with pN0
disease among the 269 patients with peripheral adenocarci-
noma.
TABLE 1.  Clinicoradiologic characteristics of patients
Overall pN0 disease
No. of patients 269 193
Age, y (mean ± SD) 63 ± 10 63 ± 10
Sex, M/F 135/134 99/94
Smoking, pack-years (median [25th-75th percentile]) 1.8 (0-37.2) 1.5 (0-34.0)
Pack-years >40 58 36
Pack-years ≤40 211 157
CEA, ng/mL (median [25th-75th percentile]) 3.7 (2.3-7.1) 3.1 (2.0-5.6)
Shortest dimension of lymph node, mm (mean ± SD) 6 ± 4 6 ± 4
Longest dimension of lymph node, mm (mean ± SD) 10 ± 6 10 ± 6
pDmax, mm (mean ± SD) 28 ± 12 27 ± 13
pDperp, mm (mean ± SD) 21 ± 9 20 ± 9
mDmax, mm (mean ± SD) 18 ± 14 16 ± 14
mDperp, mm (mean ± SD) 13 ± 11 11 ± 11
TDR (mean ± SD) 0.59 ± 0.30 0.64 ± 0.31
TABLE 2. Relationship between clinicoradiologic factors and pN0 disease: Univariate analysis
Variable Odds ratio 95% CI P value
Age 1.00 0.98-1.03 .8
Sex (M vs F) 1.17 0.69-1.99 .6
Smoking (pack-years >40 vs ≤40) 0.56 0.31-1.04 .07
CEA* 0.20 0.10-0.38 <.0001
Shortest dimension of lymph node (mm) 0.94 0.88-1.00 .04
Longest dimension of lymph node (mm) 0.96 0.92-1.01 .1
pDmax (mm) 0.98 0.96-1.00 .06
pDperp (mm) 0.95 0.92-0.98 .002
mDmax (mm) 0.97 0.95-0.99 .0006
mDperp (mm) 0.95 0.93-0.98 .0001
TDR 8.38 3.17-22.1 <.0001
CI, Confidence interval.
*Log-transformed serum CEA levels were used.
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Univariate analysis revealed 6 potential factors related to
pN0 disease (Table 2): TDR; pDperp; mDmax; mDperp;
serum CEA level; and the shortest dimension of lymph nodes.
The serum CEA level was significant in all multivariable
models. Lymph node size on CT scanning was not significant
in any model. TDR was a more clinically useful predictor of
pN0 disease than pDmax, pDperp, mDmax, or mDperp
because both a level of significance on TDR and a determi-
nation coefficient were the highest in model 1 (Table 3).
We compared the positive predictive value (PPV) of pN0
disease diagnosis in the overall group of patients with that
in patients with a normal CEA level and those with an ele-
vated CEA level according to various TDR cutoff levels
(Table 4 and Figure 2). Among 59 patients predicted to have
pN0 disease because of a normal preoperative CEA level
and a TDR of 0.8 or greater, 58 (98%) patients had true pN0
disease, and the remaining patient pathologic N1 disease.
A comparison between CT size criterion and criteria
combining serum CEA level and TDR in diagnosing pN0
disease is presented in Table 5. We used the CT size criteri-
on whereby lymph nodes smaller than 1.0 cm in the short-
est dimension were considered not to be metastatic.
Specificity and PPV were much higher when criteria com-
bining serum CEA level and TDR were used rather than CT
size criterion alone.
Discussion
The accurate preoperative determination of the lack of
necessity of systematic mediastinal lymph node dissection
in patients with peripheral adenocarcinoma of the lung
could have an effect on reducing operation time, degree of
invasiveness, and perhaps rapidity of patient recovery.
However, no criteria permitting such a determination have
yet been established.
The majority of lung adenocarcinomas show a mixture of
several subtypes: acinar; papillary; bronchioloalveolar car-
cinoma (BAC); and solid adenocarcinoma with mucin.4
They frequently possess a fibrotic focus or scar in the cen-
ter or beneath the pleura.7
BAC is a particular form of lung adenocarcinoma that
demonstrates a lepidic growth pattern of tumor cells along
the pre-existent alveolar septa. BAC was newly defined as
TABLE 3. Relationship between clinicoradiologic factors and pN0 disease: Multivariable analysis
Independent variables* Odds ratio 95% CI P value
Model 1 (R2 = 0.16)
CEA* 0.20 0.10-0.41 <.0001
TDR 6.97 2.33-20.9 .0005
Model 2 (R2 = 0.12)
CEA* 0.18 0.09-0.37 <.0001
pDmax 0.99 0.97-1.02 .5
Model 3 (R2 = 0.14)
CEA* 0.19 0.10-0.39 <.0001
pDperp 0.96 0.93-1.00 .03
Model 4 (R2 = 0.14)
CEA* 0.21 0.10-0.41 <.0001
mDmax 0.97 0.95-1.00 .01
Model 5 (R2 = 0.14)
CEA* 0.21 0.10-0.42 <.0001
mDperp 0.95 0.93-0.99 .005
CI, Confidence interval; R2, determination coefficient.
*Age, sex, smoking status, and the shortest and longest dimensions of pulmonary-mediastinal lymph nodes were also included in the models.
†Log-transformed serum CEA levels were used.
TABLE 4. PPVs of pN0 disease diagnosis in overall patients compared with those in patients with a normal CEA level and
those with an elevated CEA level according to various TDR cutoff levels
TDR Overall (n = 269) CEA <5.0 ng/mL (n = 167) CEA ≥5.0 ng/mL (n = 102)
≥0.9 59/64* (92) 46/47 (98) 13/17 (76)
≥0.8 76/81 (94) 58/59 (98) 18/22 (82)
≥0.7 98/113 (87) 75/80 (94) 23/33 (70)
≥0.5 125/156 (80) 94/106 (89) 31/50 (62)
≥0.3 158/218 (72) 115/140 (82) 43/78 (55)
*Number of patients with pN0 disease/number of patients predicted as having pN0 disease on the basis of TDR cutoff level (values in parentheses are
given as percentages [PPVs]).
Takamochi et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 2 329
TX
ET
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
G
TS
an adenocarcinoma without invasive components (ie, stro-
mal, vascular, or pleural invasion) in the latest World Health
Organization classification of lung tumor.4 Noguchi and
colleagues8 reported that the prognosis of adenocarcinomas
without a replacement growth pattern (BAC component) is
worse than that for adenocarcinomas with a BAC compo-
nent. The increased prevalence of a BAC component in ade-
nocarcinoma may predict a good prognosis.9
Shimosato and associataes7 first proposed that a central
fibrotic focus in lung adenocarcinoma was an important
prognostic factor. Suzuki and colleagues10 showed that the
maximum dimension of central fibrosis on pathologic spec-
imens was an independent prognostic factor for peripheral
adenocarcinoma of 3 cm or smaller in maximum dimension.
Although fibrotic foci and adenocarcinoma components
other than BAC are usually depicted as high-density areas or
consolidation on CT scans, the BAC component is reported
to be depicted as a hazy increased density area or ground-
glass attenuation on high-resolution CT scanning.11,12 Jang
and coworkers12 demonstrated that ground-glass attenuation
on high-resolution CT scanning might represent an early
stage of localized BAC.
On the basis of these findings, we speculated that a
smaller size of high-density area and a larger size of hazy
increased density area on CT scan could be a predictor of
less invasive adenocarcinoma. We proposed a new radiolog-
ic parameter, TDR, which was calculated from the tumor
shadow sizes on pulmonary window setting images and
those on mediastinal window setting images. High-density
areas in a tumor shadow on pulmonary window setting
images would be preserved on mediastinal window setting
images, and hazy increased density areas on pulmonary
window setting images would disappear on mediastinal
window setting images. TDR might represent the ratio of
BAC component to invasive component in a tumor. Because
a higher TDR would indicate a less invasive lesion, pN0 dis-
ease percentage in higher TDR cases would be higher. In
Figure 2. The PPVs of pN0 disease diagnosis in overall patients (diamonds) compared with those in patients with a
normal CEA level (squares) and those with an elevated CEA level (triangles) according to various TDR cutoff levels.
TABLE 5. Comparison between CT size criterion and criteri-
on combining serum CEA level and TDR in diagnosing pN0
disease
CT size Criterion
criterion* combining 
CEA and TDR†
No. of predicted patients with pN0 disease 211 59
No. of patients with pN0 disease 154 58
Sensitivity (%) 80 30
Specificity (%) 25 99
Accuracy (%) 64 49
PPV (%) 73 98
NPV (%) 33 36
*N0 disease was defined when all detected lymph node were smaller than
1.0 cm in the shortest dimension.
†N0 disease was predicted when serum CEA level was less than 5.0 ng/mL
and TDR was 0.8 or larger.
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this study we confirmed that a higher TDR was indeed a sig-
nificant predictor of pN0 disease in peripheral adenocarci-
noma of the lung.
The other significant predictor of pN0 disease was a nor-
mal serum CEA level. We previously reported that in
patients with an elevated CEA level, there was a good prob-
ability even for normal-sized nodes to be metastatic.13,14
Although the serum CEA level is known to vary depending
on smoking status,15 serum CEA level did not show multi-
colinearity with smoking status (Pearson correlation coeffi-
cient = 0.23). Furthermore, in multivariable analyses, serum
CEA level was proved to be a significant predictor of pN0
disease independent of smoking status.
We showed that cases of pN0 disease can be predicted
more correctly by combining preoperative serum CEA level
and TDR. Among 59 patients with a normal preoperative
CEA level and TDR of 0.8 or greater, all patients but one
had pN0 disease. The other patient had pathologic N1 dis-
ease. Although this result does not preclude the need for
hilar lymphadenectomy, systematic mediastinal lym-
phadenectomy may be avoided in this population.
Today, video-assisted thoracic surgery (VATS) is applied
to a wide variety of thoracic operations.16,17 One of the
important issues concerning VATS lung cancer resection
involves the technical difficulties in performing complete
mediastinal lymphadenectomy.2 Patients predicted as hav-
ing pN0 disease on the basis of serum CEA level and TDR
may be good candidates for VATS lung resection.
Specificity and PPV for the diagnosis of pN0 disease were
much higher when based on serum CEA level and TDR than
when based only on CT size criterion. In deciding not to per-
form lymphadenectomy, both the specificity and PPV of pN0
disease prediction must be as high as possible because patients
who did have hilar-mediastinal node involvement might lose a
chance for cure by lymphadenectomy.18 According to the
combined criteria of serum CEA level and TDR, 59 (22%) of
269 patients had correct diagnoses of not having mediastinal
node involvement. We could have avoided unnecessary medi-
astinal lymphadenectomy in about one fifth of all patients with
peripheral adenocarcinoma patients.
In conclusion, mediastinal lymph node involvement was
not found in patients with a normal preoperative serum CEA
level and a TDR of 0.8 or greater. The patients who meet
these criteria may be successfully managed by major lung
resection without systematic mediastinal lymphadenectomy.
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